Literature DB >> 2928550

Hepatic metastases: liposomal Gd-DTPA-enhanced MR imaging.

E C Unger1, T Winokur, P MacDougall, J Rosenblum, M Clair, R Gatenby, C Tilcock.   

Abstract

Liposomal gadolinium diethylenetriaminepentaacetic acid (DTPA) encapsulated within 70- and 400-nm vesicles was tested as a contrast agent for magnetic resonance (MR) imaging of the liver in rats with hepatic metastases. Liposomal Gd-DTPA caused significant improvement in contrast between liver and tumor (P less than .005) on T1-weighted MR images. Smaller 70-nm liposomal Gd-DTPA vesicles caused greater contrast enhancement, reflecting the larger surface-area-to-volume ratio of the smaller vesicles. Liposomal Gd-DTPA-enhanced images permitted significant improvement in metastasis detection by five blinded radiologists (P less than .005). By comparison, free Gd-DTPA without liposomes caused a statistically significant reduction in contrast between tumor and liver and reduced lesion detection (P less than .01). Liposomal Gd-DTPA also resulted in sustained vascular enhancement for 1 hour after administration. The results suggest that paramagnetic liposomes may become a useful MR imaging contrast agent.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2928550     DOI: 10.1148/radiology.171.1.2928550

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  16 in total

Review 1.  Imaging and drug delivery using theranostic nanoparticles.

Authors:  Siti M Janib; Ara S Moses; J Andrew MacKay
Journal:  Adv Drug Deliv Rev       Date:  2010-08-13       Impact factor: 15.470

2.  Blood oxygen level dependent angiography (BOLDangio) and its potential applications in cancer research.

Authors:  Kejia Cai; Adam Shore; Anup Singh; Mohammad Haris; Teruyuki Hiraki; Prianka Waghray; Damodar Reddy; Joel H Greenberg; Ravinder Reddy
Journal:  NMR Biomed       Date:  2012-02-02       Impact factor: 4.044

Review 3.  Rationale for and measurement of liposomal drug delivery with hyperthermia using non-invasive imaging techniques.

Authors:  Jessica A Tashjian; Mark W Dewhirst; David Needham; Benjamin L Viglianti
Journal:  Int J Hyperthermia       Date:  2008-02       Impact factor: 3.914

Review 4.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

5.  Size-induced enhancement of chemical exchange saturation transfer (CEST) contrast in liposomes.

Authors:  Jason M Zhao; Yah-el Har-el; Michael T McMahon; Jinyuan Zhou; A Dean Sherry; George Sgouros; Jeff W M Bulte; Peter C M van Zijl
Journal:  J Am Chem Soc       Date:  2008-03-25       Impact factor: 15.419

6.  MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA.

Authors:  Xiaoli Liu; Achuthamangalam B Madhankumar; Patti A Miller; Kari A Duck; Susan Hafenstein; Elias Rizk; Becky Slagle-Webb; Jonas M Sheehan; James R Connor; Qing X Yang
Journal:  Neuro Oncol       Date:  2015-10-31       Impact factor: 12.300

Review 7.  Paramagnetic liposome nanoparticles for cellular and tumour imaging.

Authors:  Nazila Kamaly; Andrew D Miller
Journal:  Int J Mol Sci       Date:  2010-04-15       Impact factor: 5.923

Review 8.  Gadolinium-based contrast agents for magnetic resonance cancer imaging.

Authors:  Zhuxian Zhou; Zheng-Rong Lu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2012-10-09

9.  T1 relaxivity of core-encapsulated gadolinium liposomal contrast agents--effect of liposome size and internal gadolinium concentration.

Authors:  Ketan Ghaghada; Catherine Hawley; Keigo Kawaji; Ananth Annapragada; Srinivasan Mukundan
Journal:  Acad Radiol       Date:  2008-10       Impact factor: 3.173

Review 10.  Targeted pharmaceutical nanocarriers for cancer therapy and imaging.

Authors:  Vladimir P Torchilin
Journal:  AAPS J       Date:  2007-05-11       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.